A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab
10.4078/jrd.2019.26.4.278
- Author:
Sang Jin LEE
1
;
Han Ki PARK
;
Yong Sun KIM
Author Information
1. Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. dream1331@naver.com
- Publication Type:Case Report
- Keywords:
Ankylosing spondylitis;
Interleukin 17A;
Neurosyphilis
- MeSH:
Ear;
Hearing Loss;
Humans;
Interleukin-17;
Neurosyphilis;
Spondylitis, Ankylosing
- From:Journal of Rheumatic Diseases
2019;26(4):278-281
- CountryRepublic of Korea
- Language:English
-
Abstract:
Anti-interleukin 17A agent, secukinumab is remarkably effective for treating patients with ankylosing spondylitis. However, the main safety concern of secukinumab is an increased risk of infection. Generally, neurosyphilis occurs a few years after the primary syphilitic infection. Rare cases of progressing to neurosyphilis with a much lower latency were reported. We report a case of rapid progressive neurosyphilis involving hearing loss in both ears in a patient with ankylosing spondylitis who was treated with secukinumab.
